Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL
Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.
United States International Workshop Venetoclax Plus Rituximab Chronic Lymphocytic Leukemia Murano Trial International Workshop On Cll
Source: onclive.com